• Molecular NameProgabide
  • SynonymHalogabide; Progabida [INN-Spanish]; Progabide [Usan:Ban:Inn]; Progabidum [INN-Latin]
  • Weight334.778
  • Drugbank_IDDB00837
  • ACS_NO62666-20-0
  • Show 3D model
  • LogP (experiment)2.97
  • LogP (predicted, AB/LogP v2.0)2.2
  • pkaN/A
  • LogD (pH=7, predicted)2.0
  • Solubility (experiment)0.0709 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.74
  • LogSw (predicted, AB/LogsW2.0)0.03
  • Sw (mg/ml) (predicted, ACD/Labs)0.61
  • No.of HBond Donors3
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds6
  • TPSA72.19
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn analog and prodrug of gamma-aminobutyric acid used in the treatment of epilepsy. It has agonistic activity at both the GABAA and GABAB receptors.
  • Absorption_valueN/A
  • Absorption (description)Well absorbed with a bioavailability of 60%
  • Caco_2N/A
  • Bioavailability60.0
  • Protein binding95.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life4 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=900 (ip)